Sandoz

Novartis cancels $1B sale of generics after antitrust concerns forced delays
Novartis cancels $1B sale of generics after antitrust concerns forced delays
Endpoints
Novartis
generics
Sandoz
antitrust
Flag link:
Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe
Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe
BioSpace
Sandoz
generics
Novartis
antitrust
Flag link:
Sandoz pledges 'stable' pricing for generics, antibiotics amid COVID-19 supply chain worries
Sandoz pledges 'stable' pricing for generics, antibiotics amid COVID-19 supply chain worries
Fierce Pharma
Sandoz
generics
antibiotics
COVID-19
coronaviruses
Flag link:
Former Novartis exec pleads guilty to generic price fixing
Former Novartis exec pleads guilty to generic price fixing
Endpoints
Novartis
Sandoz
price fixing
generics
DOJ
Flag link:
Sandoz Completes Acquisition of Aspen's Japanese Operations
Sandoz Completes Acquisition of Aspen's Japanese Operations
BioSpace
Sandoz
Aspen Global
Japan
M&A
Novartis
Flag link:
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Fierce Pharma
Novartis
Sandoz
United Therapeutics
Remodulin
Flag link:
Novartis' Generics Unit to Buy Aspen's Japanese Operations
Novartis' Generics Unit to Buy Aspen's Japanese Operations
Yahoo/Zacks.com
Novartis
generics
Sandoz
M&A
Japan
Aspen Pharmacare
Aspen Global
Flag link:
Novartis takes a step back from marketing Pear prescription digital therapeutics
Novartis takes a step back from marketing Pear prescription digital therapeutics
Biopharma Dive
Novartis
Sandoz
Pear Therapeutics
digital therapeutics
opioid abuse
Flag link:
Why Bausch Health Companies Stock Sank Today
Why Bausch Health Companies Stock Sank Today
Motley Fool
Bausch Health
Novartis
Sandoz
Xifaxan
patents
Flag link:
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Pharmaforum
Novartis
Sandoz
generics
biosimilars
Tysabri
Polpharma
Flag link:
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
Amgen
Enbrel
patents
Erelzi
Flag link:
Enbrel ruling lifts Amgen shares
Enbrel ruling lifts Amgen shares
BioCentury
Amgen
Enbrel
patents
Sandoz
generics
Flag link:
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
Flag link:
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts
Fierce Pharma
Novartis
generics
Sandoz
Flag link:
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Fierce Pharma
Novartis
Mylan
Pfizer
EpiPens
Sandoz
Symjepi
drug launches
Adamis Pharmaceuticals
Flag link:
Sandoz launches oncology generic gefitinib in 13 EU countries
Sandoz launches oncology generic gefitinib in 13 EU countries
Pharmaceutical Business Review
Sandoz
Novartis
generics
gefitinib
metastatic non-small cell lung cancer
Flag link:
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlement
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlement
Fierce Pharma
Sanofi
bloodthinners
Lovenox
generics
Amphastar
Momenta
Sandoz
Flag link:
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Endpoints
Novartis
R&D
Sandoz
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Fierce Pharma
digital pharma
Sandoz
Novartis
Flag link:
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Yahoo/Reuters
Novartis
Sandoz
generics
price fixing
Flag link:

Pages